MétaCan
Menu
Back to cohort

Abstract 4357286: Atorvastatin and Pulse Wave Velocity in Anthracycline-based Chemotherapy

2025· article· en· W4415791387 on OpenAlexaff
Vencel Juhász, Zsófia D. Drobni, Thiago Quinaglia, Hannah Gilman, Giselle Alexandra Suero‐Abreu, Azin Ghamari, Julius C. Heemelaar, Donna Neuberg, Yuchi Han, Bonnie Ky, Raymond Y. Kwong, James L. Januzzi, Aarti Asnani, Negareh Mousavi, Robert Redd, Michael Jerosch‐Herold, Marielle Scherrer‐Crosbie, Tomas G. Neilan

Bibliographic record

VenueCirculation · 2025
Typearticle
Languageen
FieldMedicine
TopicChemotherapy-induced cardiotoxicity and mitigation
Canadian institutionsMcGill University
Fundersnot available
KeywordsAtorvastatinPulse wave velocityClinical endpointAnthracyclinePlaceboAdverse effect

Abstract

fetched live from OpenAlex

Background: Increased aortic stiffness is associated with cardiovascular morbidity and mortality, and is an adverse effect of anthracyclines. To date, there is no evidence-supported intervention that preserves vascular function among anthracycline recipients. While statins have been shown to preserve vascular function in patients not treated with anthracyclines, their effectiveness in patients treated with anthracyclines remains unclear. Hypothesis: We hypothesized that atorvastatin would protect against the anthracycline-induced deterioration of vascular function, assessed by aortic pulse wave velocity (PWV). Methods: We conducted a post-hoc analysis of cardiac MRI-derived PWV data from participants with newly diagnosed lymphoma in the STOP-CA trial, who were scheduled to undergo anthracycline-based chemotherapy and randomized to atorvastatin or placebo for 12 months. In patients with available data, PWV was measured at baseline and 12 months. The primary endpoint was a ≥1 standard deviation (SD) increase in PWV. The secondary endpoint was a ≥0.15 m/s increase, a previously identified mean annual rise in patients with increased cardiovascular risk. Incident heart failure (HF) events were evaluated at 24 months. Results: Paired PWV data were available in 152 participants (mean age 51±16 years, 47% female, 82 with atorvastatin). Age (median 56 for atorvastatin vs. 52 years for placebo, p=0.11) and baseline PWV were higher in the atorvastatin group (6.5±1.9 vs. 5.7±1.8 m/s, p=0.016). At 12 months, PWV was similar between the groups (6.5±2.0 vs. 6.8±2.0 m/s, p=0.47). The mean interval change in PWV was significantly lower in the atorvastatin group (0.1±0.5 vs. 1.0±0.9 m/s, p<0.001). A ≥1SD increase (0.8 m/s) was observed in 5% of the atorvastatin and 50% of the placebo groups (odds ratio [OR] 0.05, 95% confidence interval [CI] 0.02-0.16, p<0.001). A ≥0.15 m/s increase in PWV was noted in 37% of the atorvastatin and 89% of the placebo group (OR 0.08, 95% CI 0.03-0.19, p<0.001). A ≥1 SD increase in PWV was associated with a mean LVEF decline of 2.7% (95% CI -4.65 to -0.81, p=0.006). All participants (n=8) who developed incident HF by 24 months had a ≥0.15 m/s increase in PWV (p=0.023). Conclusion: In lymphoma patients undergoing anthracycline-based chemotherapy, atorvastatin demonstrated vasculoprotective effects by reducing the odds of a significant increase in aortic stiffness over 12 months. An increase in PWV may be associated with a higher risk for subsequent HF events.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.012

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.020
GPT teacher head0.290
Teacher spread0.270 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueCirculationSame topicChemotherapy-induced cardiotoxicity and mitigationFrench-language works237,207